GT Biopharma GTBP Institutional Ownership

GT Biopharma, Inc. (NASDAQ:GTBP) is held by 60 institutional investors per 13F filings through June 2026.

• These investors collectively held 7.0% of GT Biopharma's outstanding shares in June 2026, up from 5.3% in March 2026.
• They increased total shares held in GT Biopharma by 42.31% from the prior quarter, while the number of investors in GTBP increased 185.71% year over year.
• During the quarter, 32 of these 60 funds increased positions in GTBP, 8 reduced exposure, and 20 held steady.
• Altogether, these fund groups held 84.69K shares in GTBP by June 2026, up by 25.18K shares quarter on quarter, and up 76.9K shares year over year.
• As of June 30, 2026, the biggest holder of GT Biopharma is VANGUARD CAPITAL MANAGEMENT LLC at 15.06K shares, representing 1.24% of shares outstanding.
• The biggest buyers of GT Biopharma for the quarter ending June 2026 included HRT FINANCIAL LP (4.29K), Everhart Financial Group, Inc. (4.0K), Opal Wealth Advisors, LLC (3.27K), Northern Trust Corp (3.02K), 49 WEALTH MANAGEMENT, LLC (2.56K).
• The largest sales of GTBP for the quarter ending June 2026 came from VANGUARD CAPITAL MANAGEMENT LLC (3.02K), UBS Group AG (1.84K), GEODE CAPITAL MANAGEMENT, LLC (1.11K), TWO SIGMA SECURITIES, LLC (736), BlackRock, Inc. (3).
• Business Quant data shows the 10 biggest positions in GT Biopharma as of June 2026 are held by VANGUARD CAPITAL MANAGEMENT LLC (15.06K), GEODE CAPITAL MANAGEMENT, LLC (10.67K), VANGUARD FIDUCIARY TRUST CO (9.04K), HRT FINANCIAL LP (4.29K), Everhart Financial Group, Inc. (4.0K), Arax Advisory Partners (3.75K), Opal Wealth Advisors, LLC (3.27K), Northern Trust Corp (3.02K), 49 WEALTH MANAGEMENT, LLC (2.56K), ALONGSIDE, LLC (2.56K).